BioSpace News Archive

Hangzhou Chance Pharmaceuticals (“Chance”), a clinical-stage biotechnology company focusing on discovering, developing and commercializing transformative inhalation therapies for the world’s most debilitating diseases, and Aerami Therapeutics, Inc. (“Aerami” ), a clinical stage biopharmaceutical company developing inhalation therapies to treat severe respiratory and chronic diseases, announced today that they have signed an exclusive license and development agreement

China Oncology Focus Limited (COF), an affiliate of Lee’s Pharmaceutical Holdings Limited (Lee’s Pharma, HKEX: 950), and Sorrento Therapeutics, Inc. (Sorrento, Nasdaq: SRNE), today announced that its anti-PD-L1 antibody, socazolimab, licensed from Sorrento to COF for the greater China territory, has been granted breakthrough therapy designation (BTD) by the China National Medical Products Administration (NMPA) to treat recurrent or metastatic cervical cancer.

Gentem Health Inc., a Silicon Valley-startup focused on helping private practices thrive financially, has raised a $10 million Series A financing round, bringing total investment to $13.7 million.

Today, Jubilant Biosys and Yale University have announced a research collaboration for multiple small molecule research programs.

Resonant Inc. (NASDAQ: RESN), a provider of radio frequency (RF) filter intellectual property connecting People and Things, has provided preliminary unaudited financial and operational results for the fourth quarter and full year ended December 31, 2020.

Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has appointed Lyndon Lien, Ph.D., an experienced biotech CEO, entrepreneur and investor, and Nanxi Liu, CEO and Co-Founder of Enplug and Co-Founder of Nanoly Bioscience, to its Board of Directors, effective February 5, 2021.

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced it has entered into securities purchase agreements with two healthcare-dedicated institutional investors for the purchase and sale of 4,000,000 shares of its common stock at a purchase price of $6.25 per share in a registered direct offering

Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on womens intimate health, today announced that the Colorado Women on Boards Coalition has recognized the company for leadership in appointing women to serve on the company board of directors.

Following a recent analysis of the North American Laboratory Information Systems market, Frost and Sullivan announced that it has awarded NovoPath LLC the 2021 North American Best Practice Award for Enabling Technology Leadership for the second time in three years

Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck, known as MSD outside of the United States and Canada.